Back to top
more

bluebird bio (BLUE)

(Real Time Quote from BATS)

$1.00 USD

1.00
5,619,848

+0.06 (6.90%)

Updated Jul 9, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod

by Zacks Equity Research

bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.

Bluebird (BLUE) Up 9.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study

by Zacks Equity Research

bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.

bluebird (BLUE) Moves 8.1% Higher: Will This Strength Last?

by Zacks Equity Research

Bluebird (BLUE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.

Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Amgen (AMGN) and bluebird (BLUE).

bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies

by Zacks Equity Research

bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for January 21st

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag

by Zacks Equity Research

Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.

Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY

by Zacks Equity Research

The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.

bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity

by Zacks Equity Research

bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.

J&J (JNJ) Begins Rolling BLA Filing of Multiple Myeloma Drug

by Zacks Equity Research

J&J (JNJ) initiates the rolling submission of its BLA to the FDA for BCMA CAR-T therapy, ciltacabtagene autoleucel to treat adults with relapsed/refractory multiple myeloma.

Bluebird (BLUE) Down 3.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 4.23% and -25.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Sorrento (SRNE) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Will Bluebird Bio (BLUE) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status

by Zacks Equity Research

GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.

bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA

by Zacks Equity Research

bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.

bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA

by Zacks Equity Research

The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.

Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

Bluebird (BLUE) Down 7.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?